(Press-News.org) The American Society of Heating, Refrigeration and Air-Conditioning Engineers, or ASHRAE, selected Jason DeGraw, a researcher with the Department of Energy’s Oak Ridge National Laboratory, as one of 23 members elevated to Fellow during its 2024 winter conference.
A thermal-fluid scientist and mechanical engineer in the Thermal Energy Storage group, DeGraw was recognized for making substantial contributions in heating, ventilation, air-conditioning and refrigeration, and the built environment. He contributes education, research, engineering design and consultation, publications, presentations and mentoring to ASHRAE. At ORNL, DeGraw works with the Building Technologies Research and Integration Center, or BTRIC, a DOE user facility.
DeGraw, who joined ORNL in 2019, served on the ASHRAE Epidemic Task Force that produced recommendations that served as a national guide for industry and building owners and set targets for minimizing outdoor airflow rates. Guidance included tactics such as using a combination of filters and air cleaners to achieve better levels of performance for air recirculated by heating, ventilation and air-conditioning systems. DeGraw further helped the organization establish standards for the control of infectious aerosols with ASHRAE Standard 241.
Prior to joining ORNL, DeGraw earned his doctorate in mechanical engineering from Pennsylvania State University, where he worked as a graduate research associate and postdoctoral scholar. He also worked in the commercial buildings research team at the National Renewable Energy Laboratory and is a member of the development team for EnergyPlus, DOE’s open-source whole-building energy simulation program.
UT-Battelle manages ORNL for DOE’s Office of Science, the single largest supporter of basic research in the physical sciences in the U.S. The Office of Science is working to address some of the most pressing challenges of our time. For more information, please visit https://energy.gov/science.
END
ORNL's Jason DeGraw named ASHRAE Fellow
2024-02-07
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Sara Federico, MD, named director of the Solid Tumor Division at St. Jude Children’s Research Hospital
2024-02-07
(Memphis, Tenn. – February 7, 2024) St. Jude Children’s Research Hospital today announced Sara M. Federico, MD, has been named director of the institution’s Solid Tumor Division within the Department of Oncology. Federico is an internationally recognized leader in pediatric oncology whose contributions have defined the landscape of treatment for high-risk childhood solid tumors, such as neuroblastoma.
“Dr. Federico’s experience will pave the way for new discoveries that will help advance cure rates for patients with high-risk cancers by identifying, testing and optimizing novel therapeutic strategies,” said Julie R. ...
Cancer researcher Craig B. Thompson named 2024 Watanabe Prize winner
2024-02-07
INDIANAPOLIS – Pioneering cancer researcher Craig B. Thompson, MD, has been named the 2024 winner of the August M. Watanabe Prize in Translational Research.
Awarded by the Indiana University School of Medicine, the Watanabe Prize is one of the nation's largest and most prestigious awards recognizing individuals focused on shepherding scientific discoveries into new therapies for patients. The prize is awarded to a senior investigator who has made a significant contribution to the field of translational science.
Thompson is the former president and chief executive officer ...
Chapman scientists code ChatGPT to design new medicine
2024-02-07
Generative artificial intelligence platforms, from ChatGPT to Midjourney, grabbed headlines in 2023. But GenAI can do more than create collaged images and help write emails — it can also design new drugs to treat disease.
Today, scientists use advanced technology to design new synthetic drug compounds with the right properties and characteristics, also known as “de novo drug design.” However, current methods can be labor-, time-, and cost-intensive.
Inspired by ChatGPT’s popularity and wondering if this approach could speed up the drug design process, scientists in the Schmid ...
Erectile dysfunction drugs may be linked to reduced risk of Alzheimer’s disease
2024-02-07
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, FEBRUARY 7, 2024
MINNEAPOLIS – The drugs used to treat erectile dysfunction may also be associated with a reduced risk of Alzheimer’s disease, according to a study published in the February 7, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study does not prove that erectile dysfunction drugs reduce the risk of Alzheimer’s disease. It only shows an association.
Erectile dysfunction drugs, which work by dilating blood vessels to allow more blood ...
Q&A: Helping robots identify objects in cluttered spaces
2024-02-07
Imagine a coffee cup sitting on a table. Now, imagine a book partially obscuring the cup. As humans, we still know what the coffee cup is even though we can't see all of it. But a robot might be confused.
Robots in warehouses and even around our houses struggle to identify and pick up objects if they are too close together, or if a space is cluttered. This is because robots lack what psychologists call "object unity," or our ability to identify things even when we can't see all of them.
Researchers at the University of Washington ...
Evaluation of ruxolitinib, a Janus Kinase inhibitor, in multiple myeloma
2024-02-07
“[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.”
BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”
In this new paper, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James ...
Blood thinners added to clot-busting medication did not improve stroke outcomes
2024-02-07
Research Highlights:
Although giving blood thinners along with clot-busting medication may help in treating heart attacks, it did not improve 90-day outcomes in people with clot-caused strokes.
Enrollment in a large clinical trial, which had been planned to include more than 1,200 patients with ischemic stroke (clot-caused stroke), was halted after an independent data and safety monitoring board found no indication of benefit among the first 500 patients.
The data analysis for the 500 enrolled participants found giving blood thinners along with clot-busting medication did not increase the risk of bleeding into the brain.
Embargoed ...
Reinforcing the diverse ways people access seafood can ensure healthy communities in the face of change
2024-02-07
(Santa Barbara, Calif.) — As climate change affects the oceans, coastal communities, particularly those at the front lines of ocean warming and sea level rise, are facing pressures that could threaten their access to aquatic foods.
“Climate change and other economic shocks are impacting how people access seafood, and typically households that are most reliant on seafood, such as those in Pacific Island countries, are most at risk,” said Jacob Eurich, a research associate at UC Santa Barbara’s Marine Science Institute, and a fisheries scientist at the Environmental Defense Fund. Which is why, he added, it is necessary to increase food system resilience in the area, ...
Non-white victims of lethal violence and suicide in the US die significantly younger than their white counterparts
2024-02-07
In the US, people of color who are killed by violence or die by suicide lose more potential years of life than white victims, according to a new study, which also explored factors that may contribute to these disparities. Gregory Zimmerman of Northeastern University in Boston, US, and colleagues present these findings in the open-access journal PLOS ONE on February 7, 2024.
Mounting evidence suggests that, among victims of violence in the US, the average number of potential years of life lost—how much longer the victim would have lived if they survived—is greater for people of color than for white people.
To deepen understanding, Zimmerman ...
Almost 1 in 5 Indian adults aged 60+ show signs of mild neurocognitive disorder, according to nationally representative data - more than previously recognized
2024-02-07
Almost 1 in 5 Indian adults aged 60+ show signs of mild neurocognitive disorder, according to nationally representative data - more than previously recognized
###
Article URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297220
Article Title: Prevalence of DSM-5 mild and major neurocognitive disorder in India: Results from the LASI-DAD
Author Countries: USA, UK, India
Funding: This work was supported by the National Institute on Aging (R01 AG051125 (JL), R01 AG030153 (JL), U01 AG064948 (JL), R01 AG070953 (ALG)). The funders had no role in study design, ...